MPL®-S to reduce the risk of infection and its sequelae

Abstract

Get full access to this article

View all access options for this article.

References

Bone RC The pathogenesis of sepsis. Ann Int Med 1991 ; 115: 457-469.

Sundar S. , Oosting HJ , Luyendijk L. , Stilma JS , Kijlstra A. Successful treatment of refractory leishmaniasis in India using antimony plus interferon gamma. J Infect Dis 1994; 170: 663-668.

Kaplan G. Recent advances in cytokine therapy in leprosy. J Infect Dis 1993; 167: S18-S22.

Ziegler EJ , Fischer CJ , Sprung CL et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429-436.

Wortel CH , Ziegler EJ , van Deventer SJ. Therapy of gram-negative sepsis in man with anti-endotoxin antibodies: a review . Prog Clin Biol Res 1991; 367: 161-178.

Agosti JM , Fischer CJ , Opal SM et al. Treatment of patients with sepsis syndrome with soluble TNF receptor (sTNFR). Abstract M4: 34th ICAAC, Orlando Florida, October 1994.

Fischer Jr CJ , Dhainaut JF , Opal SM et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind placebo controlled trial. JAMA 1994; 271: 1876-1878.

Ribi E. , Cantrell JL , Takayama K. et al. Lipid A and immunotherapy. Rev Infect Dis 1984; 6: 567-572.

10.

Ribi E. , Amano K. , Cantrell J. et al. Preparation and anti-tumor activity of nontoxic lipid A. Cancer Immunol Immunother 1982; 12: 91-96.

11.

Data on file, Ribi Immunochem Research Inc.

12.

Data on file, Ribi Immunochem Research Inc.

13.

Rackow EC , Astiz MK , Kim YB , Weil MH Monophosphoryl lipid A blocks the hemodynamic effects of lethal endotoxemia . J Lab Clin Med 1989; 113: 112-117.

14.

Carpati CM , Astiz ME , Rackow EC et al. Monophosphoryl lipid A attenuates the effects of endotoxic shock in pigs. J Lab Clin Med 1992; 119: 323-324, 346-353.

15.

Ulrich JT , Rechtman DJ Prophylactic use of monophosphoryl lipid A in sepsis and septic shock. Abstract 1362, 6th International Congress for Infectious Diseases, Prague Czech Republic, 1994.

16.

Data on file, Ribi ImmunoChem Research Inc.

17.

Sung KM , Battafarano MD , Dahlberg PS , Dunn DL Protective effect of monophosphoryl lipid A during systemic candidiasis in neutropenic and normal mice. Submitted.

18.

Gustafson G. Personal communication.

19.

Astiz ME, Rackow EC. Unpublished data.

20.

Siver GM. Unpublished data.

21.

Data on file, Ribi Immunochem Research Inc.

22.

Astiz ME , Rackow EC , Still JG et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial. Crit Care Med 1995; 23: 9-17.

23.

Rechtman DJ , Ulrich JT , Von Eschen K. , Vargas R. , Lee M. Circulating cytokine levels following infusion of MPL® are modified by steroid in a dose dependant sometimes biphasic manner. Abstract, 33rd ICAAC, New Orleans, LA, October 1993.

24.

VanCott TC , Kaminski R. , Kalyanaraman V. et al. Analysis of the immune response to an affinity-purified oligomeric GP160 protein. Abstract, 2nd Natl Conf of Human Retroviruses and Related Infections, January 1995.

25.

Baker PJ , Hiemaux JR , Fauntleroy MB , Prescott B. , Cantrell JL , Rudbach JA Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A. Infect Immun 1988; 56: 1076-1083.